Deucravacitinib Therapeutic Cheat Sheet
Psoriasis is one of the most common immune-mediated inflammatory dermatoses, with increasing evidence for systemic comorbidities. Targeted systemic agents have revolutionized the management of moderate-to-severe psoriasis, with life-changing outcomes for many patients with the chronic disease. Injectable biologics, blocking interleukin (IL)-23 or IL-17 cytokine pathways, have become invaluable opt …
Psoriasis is one of the most common immune-mediated inflammatory dermatoses, with increasing evidence for systemic comorbidities. Targeted systemic agents have revolutionized the management of moderate-to-severe psoriasis, with life-changing outcomes for many patients with the chronic disease. Injectable biologics, blocking interleukin (IL)-23 or IL-17 cytokine pathways, have become invaluable opt … 
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- …